Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) and Kiromic BioPharma (NASDAQ:KRBP – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Institutional & Insider Ownership
60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 10.9% of Kiromic BioPharma shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 20.6% of Kiromic BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings for Aligos Therapeutics and Kiromic BioPharma, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Aligos Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Kiromic BioPharma | 0 | 0 | 0 | 0 | 0.00 |
Valuation and Earnings
This table compares Aligos Therapeutics and Kiromic BioPharma”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Aligos Therapeutics | $6.00 million | 10.09 | -$87.68 million | ($13.32) | -1.27 |
Kiromic BioPharma | N/A | N/A | -$26.90 million | ($3.50) | -0.43 |
Kiromic BioPharma has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Kiromic BioPharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Aligos Therapeutics has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.
Profitability
This table compares Aligos Therapeutics and Kiromic BioPharma’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Aligos Therapeutics | -1,283.19% | -114.34% | -64.58% |
Kiromic BioPharma | N/A | N/A | -277.46% |
Summary
Aligos Therapeutics beats Kiromic BioPharma on 7 of the 13 factors compared between the two stocks.
About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Kiromic BioPharma
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.